By Richard Gliklich

As concerns have emerged in recent years over medications such as Vioxx and now Avandia, the need to improve the surveillance of approved drugs has become increasingly apparent. To ensure the success of the drugs they develop, biomedical researchers should track a wider set of clinical endpoints in drug trials and prepare to distinguish between real and false risks suggested by long-term safety monitoring. (Click here to continue reading).